Ophthalmic complications in juvenile Graves' Disease - clinic and therapeutic approaches.

Ophthalmic complications in juvenile Graves' Disease - clinic and therapeutic approaches. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Ophthalmic complications in juvenile Graves' Disease - clinic and therapeutic approaches. Abstract Text:

Graves' Disease (GD) is the most common cause of juvenile thyrotoxicosis in children and adolescents. Regarding its treatment, there are wide differences between individual physicians' regimes and those of physicians in different countries. While Antithyroid Drugs (ATDs) remain the initial treatment of choice in almost all the medical centers in Europe, with surgery used mainly to deal with antithyroid failures, there is increasing interest, especially in US, in the use of radioiodine. Although there are data reporting no significant increase in thyroid neoplasia or gonadal injury in older children and adults receiving outpatient doses of radioiodine, endocrinologists and parents continue to shy away from this therapy, especially in Europe, in young children. Nor is there any increase in congenital abnormalities in the offspring of the adults. Thyroid Eye Disease (TED) is one of the most common manifestations of GD, the pathophysiology of which is not very well understood. However, studies by several investigators have begun to shed light on the many complex factors contributing to the development of ocular symptoms in TED. Thyroid ophthalmopathy in juvenile GD is more common but less severe and more likely to remit completely. Steroids and decompression surgery will very rarely be needed in early childhood. It has to be kept in mind that prolonged prednisone administration, which should be used in some severe cases of TED, is associated with weight gain, immune suppression and growth failure in children. Recent studies have shown successful therapy with the long-acting somatostatin analogues (SM-a), octreotide and lanreotide in adult patients with active TED. The rationale of this therapy is based on recent studies in which somatostatin receptors have been identified within the orbital tissues in TED, both in vitro and in vivo. We recently had the opportunity to treat 3 adolescents with moderately severe TED with SM-a. All had increased clinical activity scores (CAS) and were euthyroid on ATD at the time of initiation of treatment. They received 20 mg octreotide (sandostatin- LAR) i.m. one injection every 30 days for 4 months. Their ophthalmopathies improved substantially and CAS decreased in all the patients. In view of the encouraging therapeutic results in these 3 pediatric patients, SM-a may prove to be a valuable treatment in juvenile ophthalmopathy and a good alternative to corticosteroids. The results using SM-a in the treatment of TED seem promising, but studies with larger numbers of patients are needed before we reach any final conclusions.

Ophthalmic complications in juvenile Graves' Disease - clinic and therapeutic approaches. Publishing Authors By Initials

For similar surgical procedures, operative: endocrine surgical procedures: thyroidectomy research abstracts see: surgical procedures, operative: endocrine surgical procedures: thyroidectomy research

PUBMED ID PMID:

MEDLINE DATE:

Ophthalmic complications in juvenile Graves' Disease - clinic and therapeutic approaches. Journal Published:

PUBLICATION TYPE: Review

Journal: Pediatric endocrinology reviews : PER

VOLUME: 1 Suppl 2

Page Numbers: 223-9; discussion 229

Journal Abbreviation:

ISSN: 1565-4753

DAY: 9

MONTH: Dec

YEAR: 2003

Ophthalmic complications in juvenile Graves' Disease - clinic and therapeutic approaches. Information

Number of References: 79

LANGUAGE: eng

NlmUniqueID: 101202124

Ophthalmic complications in juvenile Graves' Disease - clinic and therapeutic approaches. Keywords Mesh Terms:

KEYWORDS: Thyroidectomy

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Ophthalmic complications in juvenile Graves' Disease - clinic and therapeutic approaches. Information

Substance Name: Prednisone

Registry Number: 53-03-2

Grant and Affiliation Information for Ophthalmic complications in juvenile Graves' Disease - clinic and therapeutic approaches.

AFFILIATION: Department of Endocrinology, Diabetes and Metabolism, Panagia General Hospital, Thessaloniki, Greece.

Country: Israel

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Pediatr Endocrinol Rev

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Ophthalmic complications in juvenile Graves' Disease - clinic and therapeutic approaches Related Publications

• Appetite, adiposity, and thyroid function.
• Basic endocrine products of adipose tissue in States of thyroid dysfunction.
• Childhood Graves' disease and its ophthalmic complications: Some sensitive issues.
• Consequences of an intracranial germ cell-tumor in a young adolescent.
• Endocrine abnormalities in Anorexia Nervosa.
• Factors associated with body mass index in adults from Northern Greece.
• Growth and growth hormone secretion in paediatric Cushing's disease.
• Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
• Ophthalmic complications in juvenile Graves' Disease - clinic and therapeutic approaches.
• Prevalence and trends of obesity in children and adults of South Europe.
• Use of somatostatin analogues in obesity.